RGS16

Across TCGA pan-cancer cohorts, RGS16 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RGS16 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher RGS16 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RGS16 expression acts as an unfavorable survival marker.

ESCA, MESO, and COAD are the cancer types where RGS16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	II,III,IV	0.089	0.522	.001	12	view →
MESO	DFS	Median	All	0.098	0.366	.039	6	view →
COAD	DFS	Median	All	0.127	0.519	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RGS16–ESCA (DFS)

Open the ESCA breakdown →